黑料官网

header-logo
GettyImages-609179959-hero
headshot

Wael Saber, MD, MS

Professor

view physician profile

Locations

  • Froedtert Hospital

Specialties

  • Medical Oncology
  • Hematology

Languages

  • Arabic, English

Education

  • MD - Doctor of Medicine
  • MS -Master of Science

Biography

Dr. Wael Saber joined the faculty of 黑料官网 (黑料官网) in 2009 as an Associate Professor of Medicine in the Division of Hematology and Oncology. He is also an Assistant Scientific Director in the () at the 黑料官网, an internationally recognized research organization that focuses on outcomes related to Hematopoietic Stem Cell Transplantation (HCT).

Dr. Saber attended medical school at Ain Shams University in Egypt, and completed his internship and residency at the Cleveland Clinic Foundation. He completed an NIH T-32 research fellowship in Hematology at the University of Wisconsin in Madison. He holds a master’s degree in population health sciences from the University of Wisconsin.

Research Interests

Dr. Saber is an attending physician in the 黑料官网 adult HCT unit, with clinical interests in hematologic malignancies. His research interests are focused on outcomes related to HCT.

Publications

  • (Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, Broglie L, Bloomquist J, Bupp C, Chen M, Devine SM, El-Jurdi N, Hamadani M, Hengen M, Huppler AH, Jaglowski S, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez W, Phelan R, Rizzo D, Saber W, Stefanski HE, Steinert P, Tuschl E, Visotcky A, Vogel R, Auletta JJ, Shaw BE, Allbee-Johnson M.) Transplant Cell Ther. 2025 Aug;31(8):505-532 PMID: 40398621 PMCID: PMC12302970 SCOPUS ID: 2-s2.0-105009874373 05/22/2025

  • (Abedin S, Martens MJ, Bolaños-Meade J, Al Malki MM, Lian Q, Runaas L, Elmariah H, Gooptu M, Larkin KT, Shaffer BC, Loren AW, Solh M, Alousi AM, Jamy OH, Perales MA, Rezvani A, Bhatt A, El Jurdi N, Yao JM, Applegate K, Kean LS, Efebera YA, Reshef R, Clark W, Leifer E, Saber W, Horowitz MM, Jones RJ, Holtan SG, Hamadani M.) Blood Adv. 2025 Jul 22;9(14):3495-3501 PMID: 40305657 PMCID: PMC12274666 SCOPUS ID: 2-s2.0-105011266148 04/30/2025

  • (Toor AA, Horton M, Khalid H, Krieger E, Lai TP, Spellman SR, Levine JE, Saber W, Stewart V, Gadalla SM.) Transplant Cell Ther. 2025 Jul 01 PMID: 40609742 SCOPUS ID: 2-s2.0-105011388715 07/04/2025

  • (Su CT, Saber W, Bansal A, Li L, Nakamura R, Cutler C, Roth JA, Wright W, Steuten L, Ramsey SD.) Transplant Cell Ther. 2025 Jul;31(7):459.e1-459.e6 PMID: 40320146 PMCID: PMC12229757 SCOPUS ID: 2-s2.0-105006706785 05/05/2025

  • (Shouval R, Strouse C, Kim S, Oloyede T, Ahmed S, Awan FT, Luan D, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Elsawy M, Ganguly S, Geethakumari PR, Greenbaum U, Hashmi H, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, Mead E, McGuirk JP, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Riedell PA, Saber W, Mirza AS, Magalhaes-Silverman M, Shpall EJ, Sorror M, Wudhikarn K, Turtle CJ, Moskop A, Pasquini MC.) Transplant Cell Ther. 2025 Jul;31(7):419-433 PMID: 40288610 SCOPUS ID: 2-s2.0-105006943366 04/28/2025

  • (Zhang T, Auer P, Spellman SR, Dong J, Saber W, Bolon YT.) Life (Basel). 2025 Jun 09;15(6) PMID: 40566581 PMCID: PMC12194788 06/26/2025

  • (Arai Y, Brazauskas R, He N, Al-Homsi AS, Chhabra S, Battiwalla M, Yanada M, Steinberg A, Diaz Perez MA, Hong S, Kanda J, Bashey A, Frangoul HA, Badawy SM, Verdonck LF, Lazarus HM, Yared JA, Hashem H, Sharma A, Aljurf M, Dias AL, Abid MB, Wirk B, Freytes CO, Zeidan AM, Gergis U, Beitinjaneh A, Askar M, Pu JJ, Lehmann LE, Rangarajan HG, Wood WA, Hashmi S, Yano S, Kako S, Ozawa Y, Doki N, Kanda Y, Fukuda T, Katayama Y, Ichinohe T, Tanaka J, Teshima T, Okamoto S, Atsuta Y, Saber W.) EJHaem. 2025 Jun;6(3):e70061 PMID: 40438703 PMCID: PMC12118588 05/29/2025

  • (Wirbel J, Andermann TM, Brooks EF, Evans L, Groth A, Dvorak M, Chakraborty M, Palushaj B, Reynolds GZM, Porter IE, Al Malki M, Rezvani A, Gooptu M, Elmariah H, Runaas L, Fei T, Martens MJ, Bolaños-Meade J, Hamadani M, Holtan S, Jenq R, Peled JU, Horowitz MM, Poston KL, Saber W, Kean LS, Perales MA, Bhatt AS.) Cell Rep Methods. 2025 May 19;5(5):101030 PMID: 40300608 PMCID: PMC12146642 SCOPUS ID: 2-s2.0-105003827989 04/30/2025

  • (Mendez KJW, Lai TP, Spellman SR, Verhulst S, Anderson J, Saber W, Gadalla SM, Aviv A.) Front Immunol. 2025;16:1524608 PMID: 40364833 PMCID: PMC12069395 SCOPUS ID: 2-s2.0-105005223381 05/14/2025

  • (de Lima M, Kebriaei P, Lanza F, Cho C, Popradi G, Kaur M, Zhang MJ, Zhang F, Shah R, Vandendries E, Asomaning K, Dorman S, Stelljes M, Marks DI, Saber W.) American Journal of Hematology. May 2025;100(5):909-912 SCOPUS ID: 2-s2.0-85218680599 05/01/2025

  • (Seber A, Arcuri LJ, Colturato VR, Souza MP, Zogbi YAN, Funke V, Lerner D, Macedo MC, Daudt L, Kerbauy MN, Zecchin VG, Duarte FB, Rabello Chiattone R, Soares RDA, Bettarello G, Vaz de Macedo A, Paton E, Monteiro TDM, Schmidt Filho J, Astigarraga CC, Scheinberg P, Vigorito AC, Vergueiro CSV, Simione A, Hashmi S, Saber W, Patel J, Bonfim CMS, Pasquini M, Flowers ME, Hamerschlak N.) Front Oncol. 2025;15:1584631 PMID: 40303999 PMCID: PMC12037578 04/30/2025

  • (DeZern AE, Goll JB, Jensen TL, Nonavinkere Srivatsan S, Gillis NK, Abel GA, Padron E, Deeg HJ, Al Baghdadi T, Liu JJ, Komrokji RS, Gore SD, Saber W, Bejar R, Walter MJ, Lindsley RC, Sherman S, DiFronzo N, Sekeres MA.) Blood Neoplasia. 2024 Sep;1(3):100026 PMID: 40453059 PMCID: PMC12082164 06/02/2025

Publications of from the

© 2025 黑料官网.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The 黑料官网 (黑料官网) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. 黑料官网 maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

黑料官网's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the 黑料官网 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.